Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in
adults with PC. Subjects may receive either placebo or treatment with at least 1 foot
receiving topical sirolimus at some time. For certain phases of the study treatment
assignment to the right and left foot will be randomized in a double blind fashion. Blood
levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be
taken through the 39-week study duration. Funding Source - FDA OOPD